Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TOP1 | P11387 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423248 | 0.78 | PPARG (0.42) | LMNASLC22A6TBXAS1TSHRNFKB1 | |
| SCHEMBL1665622 | 0.78 | TOP1 (0.67) | LMNASLC22A6TSHRGPR84MAPT | |
| SCHEMBL29715627 | 0.76 | TOP1 (0.55) | LMNAMAPTPPARGKMT2ATOP1 | |
| SCHEMBL7194953 | 0.75 | GPR84 (0.52) | CAMK2ALMNATBXAS1TSHRNFKB1 | |
| SCHEMBL5460849 | 0.75 | — | — | |
| SCHEMBL11291647 | 0.74 | — | — | |
| SCHEMBL8149939 | 0.74 | PPARG (0.69) | LMNASLC22A6TSHRGPR84FFAR1 | |
| SCHEMBL29724318 | 0.74 | PPARG (0.69) | LMNASLC22A6TSHRGPR84FFAR1 | |
| SCHEMBL3341235 | 0.74 | PPARG (0.69) | LMNASLC22A6TSHRGPR84FFAR1 | |
| SCHEMBL11410056 | 0.74 | F7 (0.69) | LMNASLC22A6TSHRGPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250347684-A1 | METABOLIC BIOMARKERS IN BLOOD SERUM FOR DIAGNOSIS OF ALZHEIMER'S DISEASE | UNIV TEXAS (US) | 2025-11-13 | — | — | US | claimed |
| US-20250347684-A1 | METABOLIC BIOMARKERS IN BLOOD SERUM FOR DIAGNOSIS OF ALZHEIMER'S DISEASE | UNIV TEXAS (US) | 2025-11-13 | — | — | US | disclosed |
| EP-1517880-B1 | PRODUCTION OF CIS-PELLITORIN AND USE AS A FLAVOURING | SYMRISE AG (DE) | 2011-01-05 | — | — | EP | disclosed |
| US-7482479-B2 | Production of cis-pellitorin and use as a flavouring | SYMRISE GMBH & CO., KG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-7247697-B2 | Coating compositions for use in golf balls | ACUSHNET COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060089419-A1 | Coating compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2006-04-27 | — | — | US | disclosed |
| US-20050234132-A1 | Production of cis-pellitorin and use as a flavouring | SYMRISE AG (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234132-A1 | Production of cis-pellitorin and use as a flavouring | NISCH, CYP8B1, DLAT | CAMK2A 1890/4885LMNA 2982/4885SLC22A6 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.